Navigation Links
Growth factor regenerates tooth supporting structures: Results of a large randomized clinical trial
Date:11/8/2010

Alexandria, Va., USA It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.

In an article titled "FGF-2 Stimulates Periodontal Regeneration: Results of a Multicenter Randomized Clinical Trial," which is published in the International and American Associations for Dental Research's Journal of Dental Research, M. Kitamura, from Osaka University Graduate School of Dentistry, Japan, and a team of researchers conducted a human clinical trial to determine the safety and effectiveness of fibroblast growth factor-2 (FGF-2) for clinical application. This is the largest study to date in the field of periodontal regenerative therapy.

A randomized, double-masked, placebo-controlled clinical trial was conducted in 253 adults afflicted with periodontitis. Periodontal surgery was performed, during which one of three different doses of FGF-2 was randomly administered to localized bone defects. Each dose of FGF-2 showed significant superiority over the standard of care (vehicle alone (p < 0.01)) for the percentage of bone fill at 36 wks after administration, and the percentage peaked in the mid-dose FGF-2 group. These results strongly support the topical application of FGF-2 can be efficacious in the regeneration of human periodontal tissue that has been destroyed by periodontitis.

"This study represents the largest multi-center human clinical trial using growth factor therapy to repair tooth-supporting osseous defects," said JDR Editor-in-Chief William Giannobile. "The tissue engineering technology has important ramifications in the treating of localized bone defects around teeth resulting from periodontal disease."

The abstract is published in the Journal of Dental Research and is available online at http://bit.ly/jdr4616.

An accompanying editorial titled "Growth Factors and Periodontal Engineering: Where Next?" has been published. In it, author Martha Somerman, University of Washington, Seattle, states "for periodontal regeneration to continue as an attractive approach for restoring tissues lost to disease versus the choice for extraction and implant placement, we must focus our efforts on developing predictable therapies that include substantial restoration of tissues to physiological health with positive outcomes over the long term (e.g., greater than 10 years), as well as containing costs for our patients." To read this editorial, log in to the online JDR at http://bit.ly/jdr2203 or contact Ingrid L. Thomas at ithomas@iadr.org for a PDF of the article.


'/>"/>

Contact: Ingrid L. Thomas
ithomas@iadr.org
703-299-8084
International & American Association for Dental Research
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Researchers create drug to keep tumor growth switched off
3. Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009
4. Kaiser Analysis Finds Record Medicaid Enrollment Growth in 2009
5. Media, small businesses invited to ACS Webinar on ways to take advantage of Chinas dynamic growth
6. Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms
7. Mayo Clinic researchers find oncogene is important in pancreatic cancer growth and spread
8. Bitter melon extract decreased breast cancer cell growth
9. A mothers sensitivity may help language growth in children with autism spectrum disorder
10. Chitosan as alternative to growth-promoting antibiotics for ruminants
11. Buy HGH Website Educates Consumers on the Pros and Cons of Human Growth Hormone Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: